TD Cowen lowered the firm’s price target on Cellebrite (CLBT) to $23 from $25 and keeps a Buy rating on the shares. Cellebrite is executing well into rising demand and AI is “emerging as a force multiplier,” the analyst tells investors. While the firm adds that the company reported “solid” Q4 results, it lowered its price target based on market contraction.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLBT:
- Buy Rating Backed by ARR Acceleration, Conservative Margins, and 20%+ Upside from 2026 Growth Drivers
- Cellebrite sees Q1 revenue $126M-$128M, consensus $125.2M
- Cellebrite sees FY26 revenue $565M-$571M, consensus $554.5M
- Cellebrite reports Q4 adjusted EPS 14c, consensus 14c
- CLBT Earnings Report this Week: Is It a Buy, Ahead of Earnings?